Changes in Serum MicroRNAs after Anti-IL-5 Biological Treatment of Severe Asthma
Autor: | Victoria Del Pozo, José M Rodrigo-Muñoz, José A Cañas, Marcela Valverde-Monge, Beatriz Sastre, Joaquín Sastre, Manuel J Rial |
---|---|
Přispěvatelé: | UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD) |
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
MAPK/ERK pathway Male Severe asthma lcsh:Chemistry 0302 clinical medicine Reslizumab Medicine Anti-Asthmatic Agents lcsh:QH301-705.5 Spectroscopy mepolizumab General Medicine Middle Aged Computer Science Applications microRNAs Treatment Outcome Biomarker (medicine) Female Signal transduction medicine.drug Adult severe asthma Medicina Antibodies Monoclonal Humanized Catalysis Article Inorganic Chemistry 03 medical and health sciences microRNA Humans Physical and Theoretical Chemistry Molecular Biology Anti-IL5 biologics Mepolizumab Asthma anti-IL5 biologics business.industry Organic Chemistry biomarkers medicine.disease reslizumab Microvesicles MicroRNAs 030104 developmental biology 030228 respiratory system Gene Expression Regulation lcsh:Biology (General) lcsh:QD1-999 Immunology Interleukin-5 business Biomarkers |
Zdroj: | International Journal of Molecular Sciences, Vol 22, Iss 3558, p 3558 (2021) Biblos-e Archivo. Repositorio Institucional de la UAM instname International Journal of Molecular Sciences Volume 22 Issue 7 |
ISSN: | 1661-6596 1422-0067 |
Popis: | There is currently enough evidence to think that miRNAs play a role in several key points in asthma, including diagnosis, severity of the disease, and response to treatment. Cells release different types of lipid double-membrane vesicles into the extracellular microenvironment, including exosomes, which function as very important elements in intercellular communication. They are capable of distributing genetic material, mRNA, mitochondrial DNA, and microRNAs (miRNAs). Serum miRNA screening was performed in order to analyze possible changes in serum miRNAs in 10 patients treated with reslizumab and 6 patients with mepolizumab after 8 weeks of treatment. The expression of miR-338-3p was altered after treatment (p < 0.05), although no significant differences between reslizumab and mepolizumab were found. Bioinformatic analysis showed that miR-338-3p regulates important pathways in asthma, such as the MAPK and TGF-β signaling pathways and the biosynthesis/degradation of glucans (p < 0.05). However, it did not correlate with an improvement in lung function. MiRNA-338-3p could be used as a biomarker of early response to reslizumab and mepolizumab in severe eosinophilic asthmatic patients. In fact, this miRNA could be involved in airway remodeling, targeting genes related to MAPK and TGF-β signaling pathways. |
Databáze: | OpenAIRE |
Externí odkaz: |